A phase I dose-escalation and pharmacokinetic (PK) study of a novel multiple-targeted receptor tyrosine kinase (RTK) inhibitor, XL647, in patients with advanced solid malignancies
Year: 2005
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: H. Wakelee, A. A. Adjei, H. Keer, J. Halsey, L. Hanson, J. Reid, S. Hutchison, J. Piens, S. Lacy, B. I. Sikic
Institutions: Mayo Clinic, Exelixis (United States), Stanford University
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W25361851